⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3301374 | 0.87 | — | — | |
| SCHEMBL9470465 | 0.87 | CCR5 (0.32) | — | |
| SCHEMBL12171340 | 0.79 | — | — | |
| SCHEMBL3992369 | 0.74 | — | — | |
| SCHEMBL14968292 | 0.71 | — | — | |
| SCHEMBL80248 | 0.71 | — | — | |
| SCHEMBL11728405 | 0.66 | — | — | |
| SCHEMBL4176836 | 0.65 | — | — | |
| SCHEMBL2363462 | 0.65 | — | — | |
| SCHEMBL18778461 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116249690-A | Indoline compounds and derivatives as EGFR inhibitors | 百济神州有限公司 | 2023-06-09 | — | — | CN | claimed |
| EP-4028125-A1 | NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | claimed |
| CN-114423747-A | Novel quinoline compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2022-04-29 | — | — | CN | claimed |
| WO-2021048200-A1 | NOVEL QUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | claimed |
| WO-2012135570-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | claimed |
| US-20100099694-A1 | 2-ANILINO-4-HETEROARYL PYRIMIDINE DERIVATIVES, AND PREPARATION THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, AND IN PARTICULAR IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-22 | — | — | US | claimed |
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | claimed |
| US-20100069417-A1 | NOVEL PHENYL(4-PHENYLPYRIMIDIN-2-YL)AMINE DERIVATIVES, THEIR PREPARATION, AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-03-18 | — | — | US | claimed |
| EP-1432718-B1 | Phosphor containing compounds with antithrombitic activity | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | EP | claimed |
| US-7572817-B2 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | claimed |
| EP-1532111-B1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | EP | claimed |
| US-20050176780-A1 | 2,5-disubstituted 3-mercaptopentanoic acid | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | claimed |
| EP-1532111-A1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | claimed |
| US-20040248852-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | claimed |
| EP-1432718-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2004-06-30 | — | — | EP | claimed |
| WO-2003106420-A1 | 2,5-DISUBSTITUTED 3-MERCAPTOPENTANOIC ACID | ASTRAZENECA AB (SE) | 2003-12-24 | — | — | WO | claimed |
| WO-2003027128-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | WO | claimed |
| WO-2024140637-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-4962096-A | WITH REDUCED PLATELET AGGREGATING ACTION | NIPPON CHEMIPHAR CO., LTD. (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0284395-A2 | Novel glycerol derivative and anti-hypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1988-09-28 | — | — | EP | disclosed |